Prenatal And Newborn Genetic Testing Market Analysis, Trends, Growth, Research And Forecast 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company presents an extensive market research report on the Prenatal And Newborn Genetic Testing Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.

Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities, providing all necessary data for thriving in the industry. This report market research offers a comprehensive perspective, including an in-depth analysis of the present and future scenarios within the industry.

Market Sizing:

The prenatal and newborn genetic testing market size has grown rapidly in recent years. It will grow from $5.87 billion in 2023 to $6.68 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to improved non-invasive prenatal testing, increased maternal age, government support and healthcare policies, patient demand for early detection..

The prenatal and newborn genetic testing market size is expected to see rapid growth in the next few years. It will grow to $10.7 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expanded genetic test panels, increasing maternal health awareness, prenatal and newborn screening guidelines, rising focus on rare diseases, ethical and regulatory considerations.. Major trends in the forecast period include non-invasive prenatal testing (nipt), genome sequencing (wgs) and whole exome sequencing, integration of artificial intelligence (ai), preimplantation genetic testing (pgt), direct-to-consumer genetic testing..

Request for free sample report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13158&type=smp

Key Market Players:

F. Hoffmann-La Roche AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton, Dickinson and Company, Quest Diagnostic Incorporated, Agilent Technologies Inc., Grifols S.A., Terumo Corporation, Illumina Inc., PerkinElmer Genomics, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen NV, Werfen S.A., DiaSorin S.p.A, Nova Biomedical, BGI Group, Natera Inc., Trinity Biotech plc, Meridian Bioscience Inc., Sekisui Diagnostics, Chembio Diagnostics, PTS Diagnostics, Ariosa Diagnostics Inc., AccuBioTech Co. Ltd., Sequenom Inc. are prominent players in the industry.

Market Drivers:

Government initiatives and support for prenatal testing and newborn genetic screening are expected to propel the growth of the prenatal and newborn genetic testing markets going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by a government at the local, regional, or national level to address a particular issue, achieve specific goals, or promote the well-being of its citizens. Government initiatives for prenatal and newborn genetic testing support the country's people by helping identify genetic conditions or abnormalities in fetuses during pregnancy or in newborns shortly after birth. For instance, in June 2022, the Australian government allocated $1.3 million annually to the New South Wales (NSW) ( a state on the east coast of Australia) newborn screening program to offer free tests for severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA), including newborn genetic testing and screening, to all new babies in the state. The screening tests would be provided to around 100,000 babies each year, saving the lives of up to 13 newborns likely to have these genetic disorders. Therefore, government initiatives and support for prenatal testing and newborn genetic screening drive the prenatal and newborn genetic testing markets.

Market Segments Include:
1) By Product Type: Consumables, Instruments
2) By Screening: Non-Invasive Prenatal Testing, Chronic Villus Sampling, Amniocentesis, Maternal Serum Screening, Other Screenings
3) By Disease: Down Syndrome, Cystic Fibrosis, Sickle Cell Anemia
4) By End User: Hospital, Maternity And Specialty Clinics, Diagnostic Centers

The report answers the following questions:
What are the primary factors propelling the market during the projected period?

In which region is the most substantial growth expected?

Which trend will take center stage in the upcoming period?

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.